Pricing of medical technologies
Drug Pricing
Tuesday, 24 July 2007
Second Generation Antiretrovirals
For older documents on second generation antiretrovirals (including both second line drugs and drugs from the revised WHO recommendations for first-line therapy in resource-poor settings), see the CPTech page on Second-Generation Antiretrovirals.
Submissions of Member States and Stakeholders to WHO Expert Working Group on R&D Financing
Submitted by thiru on 11. May 2009 - 7:22The contributions from WHO Member States and other Stakeholders to the Expert Working Group on R&D financing are now available on the WHO website.
The following extract is taken from the WHO public hearing website:
KEI comments to WHO EWG
Submitted by James Love on 16. April 2009 - 10:32KEI filed comments with the WHO Expert Working Group. A copy is available here.
EC’s two medicines in transit exceptions
Submitted by James Love on 24. March 2009 - 6:00At the WIPO SCP coffee break, one attendee explained to KEI that the EU has in two places, (1) the regulations on tiered pricing, and (2) the implementation of the WTO’s 30 August 2003 decision on compulsory licensing, created an exception for goods in transit to developing countries.
NGO views: World Health Organization (WHO) voice on issue of medicines in transit to developing countries?
Submitted by thiru on 13. March 2009 - 3:51On 18 February 2009, 16 civil society groups sent a letter to Director-General Dr. Chan on the matter of the Dutch seizures of generic medicines in-transit to developing countries. In the letter, Dr.
PhRMA Special 301 submission on Thailand
Submitted by James Love on 12. March 2009 - 16:11The following discusses the 2009 PhRMA submission for the USTR Special 301 list on Thailand. Thailand is one of three Asian countries (China, Philippines and Thailand) that were singled out by PhRMA for the harshest treatment. The submission on Thailand covers several topics, including these:
PhRMA’s Aggressive Special 301 submission for the Philippines
Submitted by James Love on 12. March 2009 - 7:01One of the more aggressive PhRMA submissions to the USTR Special 301 list is the section on the Philippines. Excerpts, which are given below, illustrate the breath of PhRMA’s demands on the USTR.
India: Intervention at WTO TRIPS Council on public health dimension of the TRIPS Agreement
Submitted by thiru on 9. March 2009 - 9:25On 3 March 2009, India delivered the following intervention at the WTO Council for TRIPS meeting on the issue of the public health dimension of the TRIPS Agreement in the context of the Dutch seizures.
_______________________________________________________________________
INTERVENTION by INDIA
Agenda item ‘M’ – OTHER BUSINESS – Public Health dimension of TRIPS Agreement
Chair,
WTO Director General Pascal Lamy’s response to joint NGO letter about seizures of medicines in trasit to developing countries
Submitted by Malini Aisola on 4. March 2009 - 12:45On 18 February 2009, sixteen NGOs sent a letter to the head of the World Trade Organization regarding a series of seizures by the Dutch custom authorities of generic medicines in transit to developing countries. The letter is available at
http://www.keionline.org/misc-docs/seizures/WTO_seizures_18feb.pdf
Today, Director General Pascal Lamy responded to the letter which is available at
